Stem cell transplantation has emerged as the most cost-effective long-term care strategy for adults with sickle cell disease in the United States, outpacing both gene therapy and standard treatment protocols.
The landmark analysis is the first to compare the economic viability of all three modalities head-to-head. Investigators found that to compete on value, the price of gene therapy would require a drastic 66 to 71 percent reduction from current assessments.
Lead author George Goshua of Yale School of Medicine and Yale Cancer Centre stated that while gene therapy represents an incredible immune innovation, it carries an astronomical financial burden. He noted recent prospective studies confirm stem cell transplantation is now safer and more efficacious for patients than in previous eras.
Sickle cell disease remains the most common inherited blood disorder, impacting nearly 8 million people globally and roughly 100,000 individuals domestically. Standard care involving hydroxyurea, pain management, and blood transfusions has historically been the default.
Researchers calculated quality-adjusted life-years and net monetary benefit to level the playing field. Gene therapy accrued 22.1 QALYs at a cost of $2.75 million. Standard of care reached 14.3 QALYs at $1.22 million. The standout method, non-myeloablative haploidentical allogeneic stem cell transplantation, achieved 20.1 QALYs at just $1.15 million.
Goshua emphasized that regardless of adjusted assumptions, the transplantation protocol delivered the best clinical value. He added that global price thresholds identified in their analyses may guide government investment for curative therapies, though access to multiple treatments remains vital for patient-centered care.